COMBINE ANNUAL MEETING 2024: Ensuring the Project’s Legacy Beyond Its Lifetime

On October 28–29, 2024, COMBINE hosted its fifth annual meeting in Tres Cantos, Spain, bringing together 23 participants, including members of the Scientific Advisory Board (SAB). The two-day event celebrated the project’s achievements while setting the stage for its future. Participants reviewed key milestones, exchanged insights, and mapped out a strategy to ensure COMBINE’s lasting impact.

The meeting opened with an overview of the past year presented by Project Coordinator Anders Karlén (Uppsala University) and Project Lead Tim Miles (GlaxoSmithKline). This was followed by an engaging lecture from SAB member and PriMAVeRa project partner Marlieke De Kraker, who discussed adaptive clinical trial designs for infectious diseases.

The presentations of work packages encouraged lively discussions among participants, with SAB members asking insightful questions and providing helpful suggestions. COMBINE expresses its appreciation to Patricia Londono-Hayes, Marlieke De Kraker, and Niels Frimodt-Møller for their valuable advice and support.

The meeting concluded with a forward-looking sustainability workshop led by Josepine Fernow (Uppsala University) and Philip Gribbon (Fraunhofer ITMP). The workshop focused on business models and provided actionable insights for ensuring COMBINE’s long-term impact. COMBINE is committed to sharing its sustainability approach with all projects under the AMR Accelerator to drive forward sustainability, innovation, and collaboration efforts.

COMBINE supports the AMR Accelerator projects’ mission to develop tools and treatments for antimicrobial resistance (AMR) and tuberculosis (TB) research. Stay tuned for updates as COMBINE continues to address one of the world’s most urgent health challenges.